Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma-Reference-Cited by-同舟云学术

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Published:2021-07-29 Issue:12 Volume:11 Page:2998-3007
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Ribas Antoni,Medina Theresa,Kirkwood John M.^ORCID,Zakharia Yousef^ORCID,Gonzalez Rene,Davar Diwakar^ORCID,Chmielowski Bartosz^ORCID,Campbell Katie M.^ORCID,Bao Riyue,Kelley Heather,Morris Aaron,Mauro David,Wooldridge James E.^ORCID,Luke Jason J.,Weiner George J.,Krieg Arthur M.,Milhem Mohammed M.

Funder

Checkmate Pharmaceuticals, Inc

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

2. Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling;Journal of Experimental & Clinical Cancer Research;2024-07-17

3. Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions;Radiology;2024-07-01

4. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases;Journal for ImmunoTherapy of Cancer;2024-07

5. The balance of STING signaling orchestrates immunity in cancer;Nature Immunology;2024-06-25